NVO - Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk Eli Lilly Ramp Up Supply | Benzinga
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications from Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY).
What Happened: The sales of weight-loss drugs from Novo Nordisk and Eli Lilly are on the rise, as per a Reuters report. The increased supply, coupled with a surge in demand and the emergence of new competitors, has led industry experts to revise their sales forecasts.
Michael Kleinrock, a senior research director at healthcare analytics firm IQVIA Institute for Data Science, noted that the medications are capturing the attention ...